OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Stake in Perspective Therapeutics, Inc. (NYSE:CATX)

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Perspective Therapeutics, Inc. (NYSE:CATX) by 73.8% during the 4th quarter, HoldingsChannel reports. The firm owned 123,243 shares of the company’s stock after buying an additional 52,320 shares during the quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Perspective Therapeutics were worth $393,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Deerfield Management Company L.P. Series C increased its position in shares of Perspective Therapeutics by 4.3% in the fourth quarter. Deerfield Management Company L.P. Series C now owns 2,938,754 shares of the company’s stock valued at $9,375,000 after buying an additional 120,991 shares in the last quarter. Octagon Capital Advisors LP increased its position in Perspective Therapeutics by 62.1% during the fourth quarter. Octagon Capital Advisors LP now owns 2,304,752 shares of the company’s stock worth $7,352,000 after purchasing an additional 882,528 shares during the last quarter. Nicholson Wealth Management Group LLC increased its holdings in shares of Perspective Therapeutics by 0.4% during the 4th quarter. Nicholson Wealth Management Group LLC now owns 1,609,283 shares of the company’s stock worth $5,134,000 after buying an additional 7,000 shares during the last quarter. Affinity Asset Advisors LLC increased its stake in Perspective Therapeutics by 160.0% during the fourth quarter. Affinity Asset Advisors LLC now owns 1,300,000 shares of the company’s stock worth $4,147,000 after acquiring an additional 800,000 shares during the last quarter. Finally, Millennium Management LLC purchased a new stake in Perspective Therapeutics in the 4th quarter valued at about $4,132,000. Institutional investors and hedge funds own 54.66% of the company’s stock.

Analyst Ratings Changes

A number of analysts have issued reports on CATX shares. Truist Financial cut their target price on Perspective Therapeutics from $21.00 to $10.00 and set a “buy” rating on the stock in a research report on Monday, April 7th. Scotiabank assumed coverage on shares of Perspective Therapeutics in a report on Friday, March 7th. They issued a “sector outperform” rating and a $15.00 target price on the stock. Brookline Capital Management raised Perspective Therapeutics to a “strong-buy” rating in a report on Monday, March 10th. Cantor Fitzgerald raised Perspective Therapeutics to a “strong-buy” rating in a report on Tuesday, March 4th. Finally, Royal Bank of Canada dropped their price objective on Perspective Therapeutics from $16.00 to $15.00 and set an “outperform” rating on the stock in a report on Thursday, March 27th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $12.75.

Insider Activity

In related news, Director Robert F. Williamson III purchased 22,192 shares of Perspective Therapeutics stock in a transaction dated Friday, March 28th. The stock was bought at an average cost of $2.27 per share, for a total transaction of $50,375.84. Following the transaction, the director now owns 70,837 shares in the company, valued at approximately $160,799.99. The trade was a 45.62% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Johan M. Spoor acquired 22,026 shares of Perspective Therapeutics stock in a transaction that occurred on Friday, March 28th. The shares were purchased at an average cost of $2.24 per share, with a total value of $49,338.24. Following the completion of the acquisition, the chief executive officer now owns 59,383 shares of the company’s stock, valued at $133,017.92. The trade was a 58.96% increase in their position. The disclosure for this purchase can be found here. Insiders have bought a total of 115,696 shares of company stock valued at $256,344 over the last quarter. Corporate insiders own 3.72% of the company’s stock.

Perspective Therapeutics Stock Performance

Perspective Therapeutics stock opened at $2.55 on Wednesday. Perspective Therapeutics, Inc. has a 12 month low of $1.60 and a 12 month high of $19.05. The business has a 50 day simple moving average of $2.25 and a 200-day simple moving average of $3.84.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.